Research & Development

Posters

Key Research Findings Presented at Leading Conferences & Meetings

01

AASLD 2025: Targeting CCL24 restores MST1 expression: A mechanistic insight from the SPRING trial

02

AASLD 2025: Nebokitug targets macrophage-mediated mechanisms in primary sclerosing cholangitis with potential impact on disease progression

03

AASLD 2025: Safety and activity of nebokitug over 48 weeks in patients with primary sclerosing cholangitis: Open label extension results from the SPRING Study

04

DDW 2025: Nebokitug (CM-101), a novel monoclonal antibody targeting CCL24, was safe and well tolerated and showed improvements of biomarkers associated with inflammation, fibrosis, and cholestasis in patients with primary sclerosing cholangitis: The SPRING Study

05

EASL 2025: Nebokitug impacts disease biomarkers in primary sclerosing cholangitis: Assessment of the SPRING study pharmacokinetics and pharmacodynamics

06

EASL 2025: CCL24 blockade alters the proteomic profile of patients with PSC and down-regulates central disease processes

07

CORA 2025: CCL24 Expression and impact on immune cell populations in systemic sclerosis

08

AASLD 2024 – Late-breaking oral presentation: CM-101 improved fibrosis biomarkers in patients with primary sclerosing cholangitis: The Phase 2 SPRING study

09

EASL 2024 – Ex-vivo translational assay of hepatic stellate cells using patient-derived serum characterizes the anti-fibrotic activity of CM-101

10

EASL 2024 – Machine learning-driven identification of serum protein signature for primary sclerosing cholangitis and enhanced liver fibrosis score

11

Gordon Research Conference on Chemotactic Cytokines – Attenuating liver fibrosis and inflammation: blocking CCL24 inhibits recruitment of hepatic stellate cells, monocytes and neutrophils and modulates hepatic stellate cell activation

12

ACR Convergence 2023-The involvement of CCR3-CCL24 axis in endothelial to mesenchymal transition process and pulmonary arterial hypertension in systemic sclerosis patients

13

AASLD 2023: Serum proteomics reveals unique association of CCL24 with disease-related pathways and signatures in primary sclerosing cholangitis

14

ASLD 2023: CM-101, a CCL24 neutralizing antibody, showed improvements in inflammatory, fibrotic, and metabolic pathways in patients with NASH: Proteomics analysis of a Phase 2a study

15

EASL 2023-Phase 2a study of CM-101, a CCL24 Neutralizing Antibody, in Patients with Nonalcoholic Steatohepatitis: A Proof-of-Concept Study

16

EASL 2023 – Serum Proteomics Reveals Association of CCL24 with Key Aspects of Primary Sclerosing Cholangitis

17

EASL 2023 – Targeting CCL24 in Primary Sclerosing Cholangitis with CM-101: Rationale and Study Design

18

EASL Biliary Conference 2023-Patient Proteomic Data and Mouse Model Reinforce the Proinflammatory Role of CCL24 in Cholestatic Disease

19

EULAR 2023-CCL24 Serum Concentration Predicts Vascular and Fibrotic Complications in Systemic Sclerosis

20

ASLD 2022 Liver Meeting – CCL24 Blockade Attenuates Biliary Inflammation by Interfering with Monocyte and Neutrophil Recruitment

21

The Union Conference on Lung Health 2022–Treatment with CM-101 Reduced Inflammatory & Fibrotic Biomarkers in Patients with COVID-19-derived Lung Damage

22

EASL 2022-Combination of Whole Liver Single Cell RNA Sequencing and Spatial Transcriptomics Reveals Specific Cell Sub-Populations and Pathways Regulated by CCL24

23

ECM Congress 2022-CCL Inhibition by CM-101 Attenuates Extracellular Matrix and Fibrotic Biomarkers in Both Patients and Experimental Murine Models

24

CCL24 overexpression resulting from bile duct injury induces an inflammatory-fibrotic vicious cycle in primary sclerosing cholangitis – AASLD 2021

25

The peri-ductular CCL24 rich niche promotes bile duct fibrosis related liver damage in primary sclerosing cholangitis – EASL 2021

26

CM-101 Demonstrates Reduction in Serum Fibrotic Biomarkers in a Phase 1b Clinical Trial – AASLD 2020

27

CM-101 A Novel CCL24 Blocking Monoclonal Antibody Demonstrates Safety, Target Engagement and Long Half- Life in a Phase 1 Clinical Trial – AASLD 2020

28

CCL24 modulates fibrosis development in Primary Sclerosing Cholangitis – EASL 2020

29

CCL24 Blocking Monoclonal Antibody Reduces Cholangiocites Proliferation in Cholestasis Models – EASL 2019

30

CM-101, a Novel CCL24 Blocking Monoclonal Antibody, Attenuates HSC Activation and Reduces Fibrosis in the TAA Murine Model – AASLD 2019

31

CCL24 -A novel target playing a significant role in Systemic Sclerosis (SSc)

32

CCL24 Blocking Monoclonal Antibody Ameliorates Liver Injury in Models of Cholestasis – EASL 2018

33

CM-101, CCL24 Blocking Antibody, Suppresses Hepatic Injury and Fibrosis in Models of NASH and Liver Fibrosis – AASLD 2018

34

Expression of CCL24 and its Receptor CCR3 in Patients with Non-Alcoholic Fatty Liver Disease – EASL 2018